Publications by authors named "N B Chaabane"
Introduction: The aim of this study was to evaluate the impact of the thoracic robotic approach in a high-volume center regarding procedures and clinical outcomes after 1,000 procedures.
Methods: In a single-center subset of the Epithor® database, a prospective cohort database of French thoracic surgery, we analyzed procedural characteristics and clinical outcomes from February 2014 to April 2023. A surgical technique for lung surgery was conducted with a four-arm closed chest with the port access approach and vascular sewing and knotting were preferred over stapling.
Article Synopsis
- - Facial neutrophilic dermatosis is a rare skin condition recently identified, characterized by crusty lesions resembling pyoderma gangrenosum, but with limited involvement of the facial area.
- - There is some debate among experts regarding its classification, with some considering it a variant of Sweet's syndrome and others treating it as a distinct entity.
- - Recent cases, including the one discussed, have noted potential links between facial neutrophilic dermatosis and conditions like ulcerative colitis, suggesting diverse clinical presentations.
Quantitative Gait Analysis (QGA) is considered as an objective measure of gait performance. In this study, we aim at designing an artificial intelligence that can efficiently predict the progression of gait quality using kinematic data obtained from QGA. For this purpose, a gait database collected from 734 patients with gait disorders is used.
View Article and Find Full Text PDFBackground/aims: During the natural course of Chronic Hepatitis B (CHB) infection, differentiation between inactive carrier (IC) and HBeAg negative CHB is a subject of ongoing debate. We studied the role of hepatitis B surface antigen (HBsAg) level as a means of differentiating between CHB and IC in a group of untreated chronic HBeAg-negative HBV-infected patients.
Study: A total of 115 HBeAg negative carriers were enrolled and followed up for>12 months; 78 as inactive carriers (IC), and 37 as active carriers (AC).
Background: Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non-small-cell lung cancer (NSCLC), yet no sufficient data supporting this strategy are available. This retrospective observational multicenter national study explored the efficacy of anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) rechallenge in advanced NSCLC patients, looking for potential clinical features associated with greater outcomes.
Patients And Methods: We retrospectively collected data from 144 advanced NSCLC patients whose disease was rechallenged with ICPis after ≥ 12 weeks of discontinuation.